Compare Johnson & Johnson (JNJ) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Abrdn Physical Platinum Shares ETF — how do they compare? Johnson & Johnson trades at $256.22 (market cap $618.09B), while Abrdn Physical Platinum Shares ETF trades at $15.19 (market cap $1.93B). The key difference: Johnson & Johnson is far larger — about 320.3× Abrdn Physical Platinum Shares ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| JNJ | PPLT | |
|---|---|---|
Market Cap | $618.09B | $1.93B |
Volume | 6,050,983 | 1,698,523 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $278.43 | $25.23 |
52-Week Low | $186.00 | $13.73 |
Typical Hold Time | 129 Days | 42 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.78, down 4.46% today, reflecting a bearish technical outlook with moving averages and oscillators signaling sell pressure. Recent news highlights platinum's underperformance versus other precious metals, with the term structure in contango suggesting adequate supply. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak technical signals and platinum's lag in the metals rally, though historical seasonality may offer contrarian hope. Risks include commodity price volatility and supply-demand dynamics. Investors should await updated financials for a clearer fundamental picture amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
